TG-C LD / Juniper Bio, Kolon Life Sci - LARVOL DELTA

Study to Determine the Safety and Tolerability of TG-C in Subjects With Back Pain Due to Degenerative Disc Disease (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Kolon TissueGene, Inc. | Trial completion date: Nov 2026 ➔ Nov 2027 | Trial primary completion date: Nov 2026 ➔ Nov 2027

Trial completion date • Trial primary completion date • Back Pain • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Pain

Study to Determine the Safety and Tolerability of TG-C in Subjects With Back Pain Due to Degenerative Disc Disease (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Kolon TissueGene, Inc.

New P1 trial • Back Pain • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Pain

JUNIPER BIOLOGICS ACQUIRES CELL-MEDIATED GENE THERAPY TG-C LD FOR TREATMENT OF KNEE OSTEOARTHRITIS (PRNewswire) - "Juniper Biologics...announced today that it has gained the licensing rights to develop and commercialize TG-C LD (TissueGene-C low dose) for the treatment of knee osteoarthritis. The $600 million USD licensing deal which covers Asia Pacific, Middle East and Africa was signed with Kolon Life Science, and is Juniper Biologics' second acquisition in as many months. Under the terms of the partnership, Juniper Biologics will be responsible for developing and commercializing TG-C LD to medical professionals and hospitals within these regions. Kolon Life Science will be responsible for supporting the development as well as supplying TG-C LD."

Licensing / partnership • CNS Disorders • Osteoarthritis • Pain